MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Depreciation & Amortization 2011-2026 | NVTA
Annual Depreciation & Amortization Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 M | 80.5 M | 39 M | 16.2 M | 13.5 M | 9.18 M | 6.55 M | 5.32 M | 2.32 M | 928 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 142 M | 928 K | 31.6 M |
Quarterly Depreciation & Amortization Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.2 M | 5 M | 35 M | - | 9.7 M | 5.8 M | 27.1 M | - | 56.8 M | 35.3 M | 16.6 M | - | 23 M | 14.5 M | 6.06 M | - | 11.1 M | 6.72 M | 3.29 M | - | 10.3 M | 6.93 M | 3.43 M | - | 5.88 M | 3.49 M | 1.73 M | - | 4.93 M | 3.25 M | 1.56 M | - | 3.72 M | 2.3 M | 1.02 M | - | 1.57 M | 967 K | 471 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.8 M | 471 K | 10.4 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
321 M | $ 113.95 | -0.77 % | $ 34.6 B |  USA |
 |
CareDx, Inc
CDNA
|
15 M | $ 17.3 | -2.92 % | $ 922 M | USA |
 |
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 16.4 | 0.61 % | $ 176 M |  China |
 |
Co-Diagnostics
CODX
|
1.11 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Aspira Women's Health
AWH
|
112 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
National Research Corporation
NRC
|
7.62 M | $ 17.24 | -0.52 % | $ 386 M | USA |
 |
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | China |
 |
Charles River Laboratories International
CRL
|
403 M | $ 168.88 | 0.33 % | $ 8.37 B | USA |
 |
Castle Biosciences
CSTL
|
16 M | $ 24.9 | 0.67 % | $ 692 M | USA |
 |
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
5.77 M | $ 15.24 | -0.78 % | $ 1.98 B | USA |
 |
Danaher Corporation
DHR
|
750 M | $ 191.24 | -0.44 % | $ 136 B | USA |
 |
DexCom
DXCM
|
252 M | $ 64.09 | 1.39 % | $ 25 B | USA |
 |
Fulgent Genetics
FLGT
|
24.9 M | $ 16.44 | 0.12 % | $ 497 M | USA |
 |
QIAGEN N.V.
QGEN
|
194 M | - | - | $ 10.6 B |  Niderland |
 |
Guardant Health
GH
|
39.7 M | $ 90.19 | 0.59 % | $ 11.3 B | USA |
 |
Anixa Biosciences
ANIX
|
38.3 K | $ 2.61 | 0.77 % | $ 84.7 K | USA |
 |
Biomerica
BMRA
|
87 K | $ 2.13 | -2.07 % | $ 4.89 M | USA |
 |
BioNano Genomics
BNGO
|
9.53 M | $ 1.13 | -1.7 % | $ 6.15 M | USA |
 |
ICON Public Limited Company
ICLR
|
488 M | $ 108.32 | -1.18 % | $ 8.93 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
425 K | $ 1.97 | - | $ 8.72 M | USA |
 |
Illumina
ILMN
|
354 M | $ 127.78 | 0.03 % | $ 20.3 B | USA |
 |
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M |  Israel |
 |
Celcuity
CELC
|
167 K | $ 113.83 | -0.35 % | $ 5.32 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
681 M | $ 275.15 | 0.21 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
70.1 M | $ 76.09 | 0.26 % | $ 5.14 B | USA |
 |
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
27.2 M | $ 497.15 | 0.23 % | $ 14.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
125 M | - | - | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
570 M | $ 199.79 | 0.37 % | $ 22.2 B | USA |
 |
Myriad Genetics
MYGN
|
53.7 M | $ 4.7 | 0.64 % | $ 435 M | USA |
 |
ENDRA Life Sciences
NDRA
|
44 K | $ 4.74 | - | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
36.1 M | $ 8.04 | 0.25 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
119 M | $ 9.63 | 0.73 % | $ 2.09 B | USA |
 |
Natera
NTRA
|
16.7 M | $ 206.6 | 0.84 % | $ 20.3 B | USA |
 |
Pacific Biosciences of California
PACB
|
13 M | $ 1.38 | -2.82 % | $ 414 M | USA |
 |
Precipio
PRPO
|
1.24 M | $ 25.98 | - | $ 41.7 M | USA |
 |
Personalis
PSNL
|
10.9 M | $ 6.38 | -3.04 % | $ 378 M | USA |
 |
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | USA |